Mentari Therapeutics merger with InMed set to close ahead of USD 200 million private placement - INM News | RalliesMentari Therapeutics merger with InMed set to close ahead of USD 200 million private placement
I
INM• Merger and financing expected to close
- Mentari Therapeutics is set to merge with InMed Pharmaceuticals, with the combined company operating as Mentari and moving to a new Nasdaq ticker.
- A $200 million private placement is expected to close immediately before the merger, alongside a previously announced $290 million private placement.
- The financings are expected to extend the cash runway into 2029, supporting Phase 2a readouts for two PACAP-targeted lead programs, including MT-002.
- Post-merger, fully converted and exercised shares outstanding are estimated at 601,195,812.
